Evenamide
From Infogalactic: the planetary knowledge core
Systematic (IUPAC) name | |
---|---|
2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide
|
|
Identifiers | |
CAS Number | 1092977-61-1 |
ATC code | None |
PubChem | CID: 25105689 |
ChemSpider | 44208827 |
Chemical data | |
Formula | C16H26N2O2 |
Molecular mass | 278.38984 g/mol |
|
|
|
Evenamide (INN) (developmental code names NW-3509, NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Nav1.3, Nav1.7, and Nav1.8, that is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia.[1][2][3][4] The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression.[3] It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015.[1]
See also
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
External links
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Pages with reference errors
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Carboxamides
- Antipsychotics
- Phenethylamines
- Sodium channel blockers
- Nervous system drug stubs